secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptiNose, Inc. (—)
CIK:        0001494650
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001494650-24-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Optinose Q1 XHANCE revenue $14.9M (+26% YoY); FDA approval for chronic sinusitis; guides FY24 rev $85-95M
--------------------------------------------------------------------------------

- Q1 net revenue $14.9M (+26% YoY); net loss $14.1M ($0.12/shr) vs $18.8M ($0.17) prior year.
- FDA approved XHANCE for chronic rhinosinusitis without nasal polyps on Mar 15, 2024 (first Rx treatment).
- FY24 guidance: XHANCE net rev $85-95M; avg rev per Rx >$230 (prev ~$220); GAAP op ex $95-101M.
- Expects positive GAAP income from operations for full year 2025.
- Completed $55M registered direct offering May 10; pro forma cash ~$100M sufficient through 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/0001494650-24-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/optn-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001494650-24-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer